- Home
- CLPT vs RIGL Comparison
CLPT vs RIGL Comparison
Compare CLPT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPT
- RIGL
- Stock Information
- Founded
- CLPT 1998
- RIGL 1996
- Country
- CLPT United States
- RIGL United States
- Employees
- CLPT N/A
- RIGL N/A
- Industry
- CLPT Medical/Dental Instruments
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- CLPT Health Care
- RIGL Health Care
- Exchange
- CLPT Nasdaq
- RIGL Nasdaq
- Market Cap
- CLPT 370.8M
- RIGL 335.5M
- IPO Year
- CLPT N/A
- RIGL 2000
- Fundamental
- Price
- CLPT $11.82
- RIGL $19.18
- Analyst Decision
- CLPT Strong Buy
- RIGL Buy
- Analyst Count
- CLPT 3
- RIGL 5
- Target Price
- CLPT $25.00
- RIGL $36.40
- AVG Volume (30 Days)
- CLPT 285.2K
- RIGL 242.8K
- Earning Date
- CLPT 05-13-2025
- RIGL 05-06-2025
- Dividend Yield
- CLPT N/A
- RIGL N/A
- EPS Growth
- CLPT N/A
- RIGL N/A
- EPS
- CLPT N/A
- RIGL 2.08
- Revenue
- CLPT $32,235,999.00
- RIGL $203,077,000.00
- Revenue This Year
- CLPT $25.97
- RIGL $16.75
- Revenue Next Year
- CLPT $33.96
- RIGL $13.74
- P/E Ratio
- CLPT N/A
- RIGL $9.21
- Revenue Growth
- CLPT 23.22
- RIGL 70.16
- 52 Week Low
- CLPT $5.11
- RIGL $7.48
- 52 Week High
- CLPT $19.22
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- CLPT 41.42
- RIGL 50.25
- Support Level
- CLPT $11.59
- RIGL $18.63
- Resistance Level
- CLPT $12.62
- RIGL $19.91
- Average True Range (ATR)
- CLPT 0.71
- RIGL 1.03
- MACD
- CLPT -0.14
- RIGL -0.06
- Stochastic Oscillator
- CLPT 9.35
- RIGL 41.58
About CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.